Studies of NSCLC have revealed that increased expression of estrogen receptor 1 (ESR1) is correlated with decreased CD4+ and CD8+ activated T cell infiltration of tumors, and increased immune checkpoint markers were found in patients who had increased ESR1 [149]. This evidence concerns the gene ESR1 and non-small cell lung carcinoma.